Queen's Gazette | Queen's University

Search form

Leading the way in critical cancer research

Queen’s professor Janet Dancey (Oncology) will serve as the next director of the NCIC Clinical Trials Group (NCIC CTG).

Dr. Dancey is internationally renowned for her expertise in developing new anti-cancer drugs.

“I am honoured to have the opportunity to lead the NCIC CTG and work with such a dedicated group of people at Queen’s, across Canada and around the world,” says Dr. Dancey. “The NCIC CTG is a world-class cancer clinical trials group, and the trials it conducts are important for advancing cancer care. There is tremendous opportunity to improve outcomes for cancer patients through personalized medicine strategies and to develop new approaches to trial design and execution.”

Dr. Dancey officially takes over from interim director Elizabeth Eisenhauer on Sept. 1.

Janet Dancey has been named the next director of the NCIC Clinical Trials Group.

“Cancer research is a cornerstone of research activity at Queen’s, and we are delighted to have Janet Dancey as the next director of the NCIC CTG,” says Richard Reznick, Dean of Queen’s Faculty of Health Sciences. “She is one of this country’s most respected oncologists and known internationally in the field of cancer clinical trials. She has an exceptional record of achievement as a scientist. I am confident that her leadership will have a significant impact on the continued success of the NCIC CTG.”

Dr. Dancey is currently director of Clinical Translational Research at the NCIC CTG. She is also director of the High Impact Clinical Trials Program at the Ontario Institute for Cancer Research, scientific director of the Canadian Cancer Clinical Trials Network (3CTN), and chair of the Experimental Therapeutics Network at Cancer Care Ontario.

Prior to joining the NCIC CTG, Dr. Dancey was associate chief of the Investigational Drug Branch in the Cancer Therapy Evaluation Program at the U.S. National Cancer Institute where she coordinated the development of over 200 phase I–III trials in experimental therapeutics.